Direxion Daily S&P Biotech Bull 3X Shares

LABU

Market cap $966M

After a relatively sluggish 2024 for mergers & acquisitions (M&A) activity in the biopharma sector, the environment could be more conducive for deals in the rest of 2025. The industry, like the rest of the capital markets, will be keeping an eye on interest rates as monetary easing by the U.S.

Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Cases of the flu have reached elevated levels as of late. This could keep healthcare stocks and ETFs with a healthcare focus on the radar for traders.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

When a new presidential administration is set to take office, there's uncertainty as to whether specific sectors could be impacted. In the case of healthcare, that's certainly the case, especially in biotech.

Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.